SURVYR

OGN

Organon & Co.
$13.74
−$0.01 (0.07%)Oct 26 close
Health CareS&P 600 CompareTechnicals
Model valuationLeans expensiveDCF base $-9
1M3M6M1Y2Y
-19%+10%+39%+68%+97%Oct 2025Oct 2026Apr 202652w high $13.8352w low $5.69
OGNSPY
Wall St. Highest PT $14.00 (+1.9%) Wall St. Avg PT $11.25 (-18.1%)
$6$8$10$12$14POC $14Hi $14Avg $11
Underwater Drawdown %Max DD -41.5%Current -0.5%
0.0%-41.5%
Relative Strength vs SPY+83.3% vs SPYOutperforming
+99%0%-99%
1W
−$0.01 (0.07%)
1M
+$0.01 (0.07%)
3M
+$0.22 (1.63%)
6M
+$0.62 (4.72%)
YTD
+$6.61 (92.68%)
1Y
+$4.65 (51.22%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
5 analysts · mean score 3.20
1 = Strong Buy · 5 = Sell
Strong Buy00%
Buy00%
Hold480%
Underperform120%
Sell00%
Wall Street consensus · as of Oct 20, 2026
Analyst price targets
Current price$13.74
Average target$11.25
−$2.49 (−18.1%) downsideaverage target vs current price
CurrentAverageMedian
Low$8.00
Median$11.50
High$14.00
12-month Wall Street target range · as of Oct 20, 2026

Third-party ratings, not SURVYR.'s views.

Health check

Quality
WeakAverageStrong
Average
Piotroski F-score 5 of 9
See the tests
  • ✓Positive net income
  • ✓Positive operating cash flow
  • ✗Return on assets improved
  • ✓Cash flow above net income
  • ✓Long-term debt / assets fell
  • ✓Current ratio improved
  • ✗No share dilution
  • ✗Gross margin improved
  • ✗Asset turnover improved

Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.

Key stats & company

Market value$3.6B
P/E (last 12 months)17.6
P/E (next 12 months, estimated)3.8
52-week range$5.69 – $13.83
Revenue growth (latest quarter vs a year ago)-2.3%
Dividend yield0.58%
Analyst consensusHold (4)
Average analyst price target$11.25 (-18%)

What they do

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive.

Healthcare · Drug Manufacturers - General
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Leans expensive
Model read-out from the numbers below, not advice. Score -2 (DCF counts double).
▼DCF (base case)below the price by 163%
▲Forward P/E vs sector3.8x vs median 18.0x
•Piotroski F-score5/9
▼Analyst target-18% (4 analysts)

Discounted cash flow

Bear
$-15
-207%
growth -6% · disc. 13.0% · term. 2.0%
Base
$-9
-163%
growth -1% · disc. 12.0% · term. 2.5%
Bull
$-2
-112%
growth 2% · disc. 11.0% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal
Today's price assumes free cash flow grows about 11% a year for 10 years.
Implied
+11%/yr
FCF, last 3 yrs
-7%/yr
FCF, last 5 yrs
n/a
Revenue, last 3 yrs
+0%/yr
Revenue, last 5 yrs
-1%/yr
Same inputs as the DCF above: trailing free cash flow 0.6B, 12.0% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.54 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)
sector median 31.2× · 18th pct
 17.6×
cheaper
Forward P/E
sector median 18.0× · 1st pct
 3.8×
cheaper
EV / EBITDA
sector median 16.2×
 –
Price / sales
sector median 3.3× · 12th pct
 0.6×
cheaper
Price / book
sector median 3.5× · 51st pct
 3.6×
pricier
FCF yield
sector median 4.0% · 98th pct
 15.7%
cheaper

Forward EPS $3.62 vs trailing $0.78 (+363% expected growth). Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
52.7%
Operating margin
–
FCF margin
9.3%
Net margin
3.4%
Return on equity
20.8%
Return on invested capital
–
Net debt / EBITDA
–
Current ratio
2.0×
Interest cover
–
Cash conversion (OCF/NI)
3.5×
Piotroski F-score 5/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✗ Asset turnover improved

Analysts

Mean target
$11
-18%
Analysts
4
Hold
Range
$8–$14
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$6.2B$187.0M$538.0M
2024$6.4B$864.0M$764.0M
2023$6.3B$1.0B$548.0M
2022$6.2B$917.0M$662.0M
2021$6.3B$1.4B–
2020$6.5B$2.2B–

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +0.2%.

For information only · Important disclosures

Grades vs sector

Momentum
97th percentile in sector
A+
12-1 return: +104.6%
Percentile within its GICS sector across the S&P 1500.
Growth
7th percentile in sector
F
Revenue growth (YoY): -2.3%
Percentile within its GICS sector across the S&P 1500.
Value
97th percentile in sector
A+
Forward E/P: 26.3% · EBITDA/EV: 14.2%
Percentile within its GICS sector across the S&P 1500.
Profitability
58th percentile in sector
B-
Profit margin: +3.4% · Return on equity: +24.0%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Held by 1 of 7 live models: Momentum Blend.

Momentum Blend
5.4% of the book · Leaders sleeve
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book
Why it's in the Momentum Blend

In the Leaders sleeve: a fast grower breaking out near its highs after an earnings-style gap.

What would knock it out: Exits if it closes below its stop of $12.98; last close $13.74, 6% above it.

Earnings & events

OGN earningsNext report in 13 days
Next report · quarter Sep 2026
Mon Nov 9, 2026Before the open
EPS consensus$0.94
Revenue consensus–
Last 4 quarters · EPS vs estimate
Jul 31, 2026$0.85est $1.07−20.6%Below estimates
Apr 30, 2026$0.71est $0.85−16.8%Below estimates
Feb 12, 2026$0.63est $0.73−13.3%Below estimates
Nov 10, 2025$1.01est $0.93+8.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-26 18:05:23 ET
24-1025-0225-0525-0825-1126-0226-0426-070.001.07
EstimateActual (beat)Actual (miss)

News & catalysts

More news
No recent headlines.
Insider trades
Drinane Juliana Papa
Head of Mfg & Supply · 2026-08-05
Sell
$200.3K
None
None · None
Sell
–

Stats refreshed 2026-10-26 18:05:23 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026